PARIS — Beiersdorf AG said Wednesday that it will collaborate with Insilico Medicine, a biotech company using artificial intelligence for drug discovery and aging research, to find new, safe bioactive ingredients that can be used as the basis for creating skin-care products.
“As part of our open innovation culture, we are always looking for new technologies and partners with strengths that compliment ours,” said May Shana’a, senior corporate vice president, research and development, at Beiersdorf. “We are able to evaluate new active ingredients significantly more quickly and more efficiently by simulating biologic effects in silico. This enables us to cater even better to the consumers’ as-yet unmet skin-care needs.”
Insilico Medicine, of Rockville, Md., has offices in six countries and regions. It recently secured $37 million in Series B funding.
Hamburg, Germany-based Beiersdorf is the maker of Nivea, La Prairie and Eucerin products. The listed company generated sales of 7.23 billion euros in 2018.
The group keeps making high-tech tie-ins. In early December, Beiersdorf said it had taken a “significant stake” in Lycl Inc., a rapidly growing Korean beauty and tech start-up, through its venture fund. The German company said the move fit strategically with its CARE+ plan to “win in skin care and drive consumer-centricity through digitization.”
Many multinational beauty companies are partnering with start-ups to get closer to and glean know-how from entrepreneurs, who have been shaking up traditional business models — especially in hot categories such as tech and natural beauty.